Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Sets Up Indian Subsidiary To Market Branded Drugs

This article was originally published in PharmAsia News

Executive Summary

Astellas Pharma has established Astellas Pharma India in Mumbai with a stake of about $3.1 million. The Indian subsidiary is intended to boost Astellas' presence in emerging markets, with a particular emphasis on immunology and urology products. Astellas India plans to release its first immunosuppressant, Prograf (tacrolimus), in the next fiscal year, followed by alpha-1 blocker Harnal for prostates and Vesicare (solifenacin) for bladder problems. The new company does not intend to sell generics of other drugs. (Click here for more - a subscription may be required

You may also be interested in...



Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.

COVID-19 Shows Remote Monitoring Can Work For Pre-Cert Program

In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.

Device Week, 18 September 2020 – Keeping The ‘Human’ In Human Factors Amidst COVID-19

In the age of coronavirus, human factors professionals are doing their best to find their way through the pandemic by putting unique twists on usability testing to see what works and what doesn’t in the new reality. That’s the topic of this week’s podcast.

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel